Literature DB >> 6467673

(2'-5') Oligo A synthetase in human polymorphonuclear cells increased activity in interferon treatment and in viral infections.

A Schattner, G Merlin, V Bregman, T Hahn, S Levin, M Revel, D Wallach.   

Abstract

The interferon (IFN)-induced enzyme 2-5A synthetase was found in human peripheral blood polymorphonuclear cells (PMNL). The average enzyme activity in a group of 15 patients with various viral infections was significantly higher (25-fold) than in healthy individuals. Eight patients with multiple sclerosis and six patients with bacterial infections were found to have normal 2-5A synthetase levels in the PMNL. Relationship of PMNL 2-5A synthetase levels to IFN was confirmed by finding enzyme increases in PMNL incubated in vitro with IFN, as well as in patients undergoing IFN therapy. These findings suggest that in PMNL, as in other cells, the level of 2-5A synthetase can be regulated by IFN and can be increased as a result of IFN information in diseases.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6467673      PMCID: PMC1536105     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  17 in total

1.  Interferon-mediated protein kinase and low-molecular-weight inhibitor of protein synthesis.

Authors:  W K Roberts; A Hovanessian; R E Brown; M J Clemens; I M Kerr
Journal:  Nature       Date:  1976-12-02       Impact factor: 49.962

2.  The role of neutrophils in antiviral defense--in vitro studies on the mechanism of antiviral inhibition.

Authors:  B T Rouse; R C Wardley; L A Babiuk; T K Mukkur
Journal:  J Immunol       Date:  1977-06       Impact factor: 5.422

3.  Herpes simplex and varicella-zoster: comparative histopathology of 77 cases.

Authors:  J McSorley; L Shapiro; M H Brownstein; K C Hsu
Journal:  Int J Dermatol       Date:  1974 Mar-Apr       Impact factor: 2.736

4.  Radioimmune, radiobinding and HPLC analysis of 2-5A and related oligonucleotides from intact cells.

Authors:  M Knight; P J Cayley; R H Silverman; D H Wreschner; C S Gilbert; R E Brown; I M Kerr
Journal:  Nature       Date:  1980-11-13       Impact factor: 49.962

5.  Synthesis of low molecular weight inhibitor of protein synthesis with enzyme from interferon-treated cells.

Authors:  A G Hovanessian; R E Brown; I M Kerr
Journal:  Nature       Date:  1977-08-11       Impact factor: 49.962

6.  Human polymorphonuclear leucocytes as mediators of antibody-dependent cellular cytotoxicity to herpes simplex virus-infected cells.

Authors:  J M Oleske; R B Ashman; S Kohl; S L Shore; S E Starr; P Wood; A J Nahmias
Journal:  Clin Exp Immunol       Date:  1977-03       Impact factor: 4.330

7.  Neutrophils in antiviral immunity: inhibition of virus replication by a mediator produced by bovine neutrophils.

Authors:  B T Rouse; L A Babiuk; P M Henson
Journal:  J Infect Dis       Date:  1980-02       Impact factor: 5.226

8.  2'5' oligo(A) polymerase activity in serum of mice infected with EMC virus or treated with interferon.

Authors:  I Krishnan; C Baglioni
Journal:  Nature       Date:  1980-06-12       Impact factor: 49.962

9.  Induction of 2',5'-oligoadenylate synthetase and interferon in mouse trigeminal ganglia infected with herpes simplex virus.

Authors:  Y Sokawa; T Ando; Y Ishihara
Journal:  Infect Immun       Date:  1980-06       Impact factor: 3.441

10.  Interferon-induced 2'-5' adenylate synthetase in vivo and interferon production in vitro by lymphocytes from systemic lupus erythematosus patients with and without circulating interferon.

Authors:  O T Preble; K Rothko; J H Klippel; R M Friedman; M I Johnston
Journal:  J Exp Med       Date:  1983-06-01       Impact factor: 14.307

View more
  2 in total

1.  Expression of biomarkers of interferon type I in patients suffering from chronic diseases.

Authors:  C Scagnolari; F Bellomi; S Trombetti; M Casato; M Carlesimo; F Bagnato; V Lavolpe; R Bruno; E Millefiorini; L Antonelli; E Girardi; O Turriziani; G Antonelli
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

2.  Increased activity of oligo-2',5'-adenylate synthetase in Down's syndrome and epilepsy.

Authors:  N Fujii; K Oguma; M Fujii; R Fukatsu; N Takahata; M Kitabatake
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.